ArticleInflammopharmacology2022

Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.

Pariya Khodabakhsh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.